Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Shakas & Shoutouts celebrates the good people, things, and events happening in our local community, here and abroad.Shakas & ...

and diabetic macular edema are under FDA review with a target action date of April 20, 2025, to potentially extend dosing intervals for Eylea HD up to every 24 weeks. Regeneron plans to submit a ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

M&As are stressful for multiple reasons, including role changes and getting laid off when staffs combine. Two talent experts ...

Patients with the ultra-rare rare disease CHAPLE could have a first approved treatment in the summer, now that the FDA has started its review of Regeneron’s dug candidate pozelimab. CHAPLE ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease. The cholesterol ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...